GlobeNewswire PharmaOriginal article
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Phase 2positiveAnti-IL-15 AntibodyPositive
AI Analysis
Summary
Teva announced advancement of its anti-IL-15 antibody into Phase 2b development for vitiligo following encouraging Phase 1b results. The company will host an investor call on July 7, 2026 to discuss the data.
Clinical Trial Data
Phase
2b
Outcome Details
Encouraging Phase 1b results
Importance:6/10
Sentiment:
0.65
Phase 2b advancementVitiligoQuarterly dosingAnti-IL-15 antibodyInvestor call
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 7, 2026 11:00 AM